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Abstract
Background: Nocturnal hemodialysis (NHD) is an alternative to conventional three times per
week hemodialysis (CvHD) and has been reported to improve several health outcomes. To date,
no randomized controlled trial (RCT) has compared NHD and CvHD. We have undertaken a
multi-center RCT in hemodialysis patients comparing the effect of N H D  t o  C v H D  o n  l e f t
ventricular (LV) mass, as measured by cardiac magnetic resonance imaging (cMR).
Methodology/design: All patients in Alberta, Canada, expressing an interest in performing NHD
are eligible for the study. Patients enrolled in the study will be randomized to either NHD or CvHD
for a six month period. All patients will have a full clinical assessment, including collection of
biochemical and cMR data at baseline and at 6 months. Both groups of patients will be monitored
biweekly to optimize blood pressure (BP) to a goal of <130/80 mmHg post-dialysis using a
predefined BP management protocol. The primary outcome is change in LV mass, a surrogate
marker for cardiac mortality, measured at baseline and 6 months. The high sensitivity and
reproducibility of cMR facilitates reduction of the required sample size and the time needed
between measures compared with echocardiography. Secondary outcomes include BP control,
anemia, mineral metabolism, health-related quality of life, and costs.
Discussion: To our knowledge, this study will be the first RCT evaluating health outcomes in
NHD. The impact of NHD on LV mass represents a clinically important outcome which will further
elucidate the potential benefits of NHD and guide future clinical endpoint studies.
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Background
Despite advances in dialysis therapy, mortality and mor-
bidity remain high for patients with end-stage renal dis-
ease (ESRD). For instance, the mortality of this very high-
risk population remains at nearly 20% per year with death
rates from cardiac disease that are 10–20 fold higher in
dialysis patients than in the general population [1]. Only
16% of incident dialysis patients have normal hearts by
echocardiography, with concentric left ventricular hyper-
trophy (LVH) present in 41% and systolic failure in 16%
[2]. This is important since the presence of LVH is associ-
ated with a several fold increase in risk for both heart fail-
ure and mortality [2,3].
Randomized trials that have attempted to demonstrate
reduction in mortality among dialysis patients have gen-
erally been unsuccessful [4-8]. Even trials designed to
impact surrogate endpoints, such as regression of LVH or
LV dilatation, have been disappointing. Furthermore,
there are very few interventions that have been shown to
improve the poor health-related quality of life (HRQOL)
observed in this population.
This difficulty of improving health outcomes may be due
to the fact that ESRD is characterized by numerous com-
plex metabolic and physiological abnormalities. Conven-
tional hemodialysis (CvHD) does not normalize the
majority of these abnormalities, and provides only a small
fraction small molecular weight solute clearance com-
pared with native kidney function[9]. In an attempt to
improve urea clearance and clinical outcomes, nocturnal
hemodialysis (NHD), a technique first developed in the
1970s, has received renewed attention. In NHD, patients
perform dialysis at home; this is done five to six nights per
week while they sleep.
Case control and cohort studies suggest that nocturnal
hemodialysis may induce regression of LVH [10-12],
improve HRQOL [13-15], and improve blood pressure
control [16-18], among other health benefits. However,
observational data may lead to conclusions ultimately
refuted by randomized clinical trials (RCT). Given the
uncertainty associated with the observed outcomes and
costs derived from non-randomized studies examining
NHD [19,20], it is important to have high quality data on
NHD before widespread uptake of this new therapy
occurs. We describe a randomized pilot trial comparing
NHD (5 or 6 nights per week, 8 hours per night) and con-
ventional hemodialysis (three times per week, four hours
per session) with respect to their effect on progression of
left ventricular mass measured by cardiac magnetic reso-
nance imaging (cMR). Data on health-related quality of
life, and measures of physiologic control, including blood
pressure, anemia, calcium and phosphate metabolism
and costs will be assessed as secondary outcomes.
Methods/design
This study will be a prospective, two-center, parallel-group
randomized, controlled study, with blinding of outcome
assessors and data analysts. Approval has been granted by
the local bioethics committees at the University of Calgary
and the University of Alberta.
Eligible patients are men or women greater than 18 years
of age who are currently receiving any hemodialysis
modality (in-center, self-care or home) excluding current
NHD. To be enrolled in this study, patients must be inter-
ested in and willing to train for NHD. Exclusion criteria
include the inability to perform NHD due to physical or
mental incapacity or the inability to provide informed
consent.
Those patients meeting the inclusion and exclusion crite-
ria will be randomized to either the NHD or control
group. Randomization will be performed using a compu-
ter generated sequence in blocks of four patients. Rand-
omization will be stratified by center and by baseline
dialytic modality (self-care/home hemodialysis vs. in-
center hemodialysis). Concealment will be assured
through the use of sealed, opaque envelopes. Given the
logistics of training patients within a nocturnal dialysis
program, randomization will occur at one time point for
patients willing to enter the study; however, patient entry
into the study (i.e. the baseline study visit) will be stag-
gered over time to facilitate NHD training in an orderly
fashion. This will create a similar number of intervention
and control patients at any given time point. This
approach will be used to avoid an imbalance in drop-out
rates between the two groups. Subjects randomized to
CvHD will be eligible to commence NHD after study exit
(six months).
Objectives
The primary objective of this study is to evaluate the
impact of NHD on the change in LV mass compared to
CvHD in ESRD patients. LV mass will be measured by
cMR at baseline and after six months of study and the dif-
ference will be compared between groups.
Secondary objectives of this study include the evaluation
of NHD, as compared to CvHD, on (1) blood pressure,
(2) HRQOL, (3) anemia, (4) mineral metabolism, and
(5) health care and non-health care-related costs.
Procedures – General considerations
Two centers in Alberta, Canada, the University of Calgary
and the University of Alberta, will actively participate in
the study. The first patient was enrolled in August 2004
and by January 2006 enrollment is expected to be com-
plete. All patients will be followed for a period of six
months for the primary and secondary objectives. GivenBMC Nephrology 2006, 7:2 http://www.biomedcentral.com/1471-2369/7/2
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the nature of the intervention, it is not possible to blind
patients and investigators to the study intervention; how-
ever, the radiologists assessing the cMR studies (i.e. out-
come assessors) and data analysts will be blinded to
patient allocation.
Formal study visits will occur at study entry and at six
months (study exit). These will be performed by physi-
cians involved in the study and will be comprised of ques-
tionnaires, standardized blood pressure measurements,
and reviews of recent dialysis sessions and laboratory
work (see Table 1). Entry and exit visits will be performed
within one week of entry and exit cMR tests. The baseline
study visit will occur immediately pre-dialysis on a mid-
week dialysis day for both groups. Exit study visits will
occur immediately pre-dialysis on a mid-week dialysis day
for the CvHD patients and ~9 hours post-dialysis (~5
hours predialysis) for NHD patients.
Procedures – Nocturnal hemodialysis
Patients will initially be trained in-center for four to five
days per week with direct nursing supervision and moni-
toring of biochemical parameters. During this training
period dry weight and medications will be adjusted as dic-
tated by blood pressure and biochemical parameters. Tar-
get weight will be adjusted over the course of the first 4
weeks to achieve a goal postdialysis blood pressure of
130/80, with introduction and discontinuation of blood
pressure medications according to the protocol outlined
below and in Figure 1. Anemia management will be car-
ried out according to a standardized nursing-led anemia
protocol aiming for a goal hemoglobin of 110 – 120 g/L
utilizing erythropoietic stimulating proteins and iron sup-
plements as necessary [21]. Mineral metabolism manage-
ment will be carried out by the patient's attending
nephrologist according to local treatment goals (calcium
< 2.55 mmol/L, phosphate <1.80 mmol/L and intact PTH
150 – 300 ng/L).
Upon completion of training, nocturnal hemodialysis
will be performed by the patients, at home, without
remote monitoring 5 – 6 nights per week for a minimum
of 6 hours per night. Dialysis will be performed with
blood flow rates of 250 ml/min in patients receiving dial-
ysis by central venous catheter or 150–200 ml/min in
patients dialyzing by a single needle, button-hole tech-
nique in a graft or fistula. Dialysate flow rates of 300 ml/
min were used for all patients.
Procedures – Conventional hemodialysis
Patients will continue their pre-randomization dialysis
modality (in-center, self-care or home hemodialysis) and
dialysis prescription. Blood pressure management will be
standardized as outlined below and in Figure 1. Anemia
and mineral metabolism management will be carried out
as per the protocols noted above for the NHD patients.
Procedures – Blood pressure treatment
Blood pressure and antihypertensive medication use are
potentially important determinants of LVH. In an attempt
to assess whether the hypothesized impact of NHD on LV
mass is due to improved BP control or to a non-BP related
effect, both arms of the study will be aggressively treated
to a post-dialysis blood pressure goal of 130/80 mmHg.
This goal will be achieved by implementation of a man-
agement algorithm (see Figure 1). Although there is con-
troversy as to the goal BP in hemodialysis patients [22],
and in addition, whether pre- or post- dialysis pressures
correlate best with cardiovascular outcomes, for the pur-
poses of this algorithm, the blood pressure of interest will
be the recording obtained by the dialysis machine's auto-
mated blood pressure cuff immediately post-dialysis.
Table 1: Data collection time points.
Data Collected Month of Study
Randomization Baseline 1 2 3 4 5 6
Baseline 
Characteristics
X X
Comorbidity Data X
cMR X X
Blood Pressure X X
HRQOL XX X
Hbg/Hct XXXXXXX
Erythropoeitin XXXXXXX
Calcium/Phosphate XXXXXXX
PTH X X
Medications XXXXXXX
Kt/V X X
Economic Data X XBMC Nephrology 2006, 7:2 http://www.biomedcentral.com/1471-2369/7/2
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Blood pressures will be reviewed and appropriate changes
made as per the blood pressure algorithm every two
weeks. Antihypertensive medications previously pre-
scribed by the patients' nephrologist will be left in place at
study entry. The protocol mandates stepwise reductions in
dry-weight as tolerated by the patient before intensifica-
tion of their pharmacologic routine. Pharmacologic inter-
vention is preferentially accomplished by first increasing
doses of already prescribed angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers fol-
lowed by beta blockers or calcium channel blockers, and
then other antihypertensives. The use of direct vasodila-
tors will be avoided when possible. If these manipulations
are not successful in achieving target blood pressure other
agents may be added.
Outcomes – Left ventricular mass
LV mass, in grams, will be measured by cMR at baseline
and at month six for patients in both arms of the study.
MR imaging will be performed in each patient using a 1.5-
T system (Sonata Software versions Syngo 2002B and
2004A; Siemens Medical Solutions, Erlangen, Germany).
ECG gating will be used for all acquisitions. Briefly, rou-
tine localizers will be obtained and a four chamber local-
izer will be used. By using the end-diastolic cine frame of
this four-chamber view, a series of parallel short-axis
image planes can be defined, starting at the base of the LV
and right ventricle (RV) and encompassing the entire LV
and RV from base to apex. The most basal image plane
will be positioned well into the atria. This will also ensure
that the most basal part of the ventricles will be covered.
The entire LV/RV will be covered with 10–12 slices (10
mm thick, gap 2 mm). At every short-axis plane, a breath-
hold cine acquisition will be performed. For cine imaging,
a steady-state free precession pulse sequence will be
applied with 15 ky lines per heartbeat. Retrospective gat-
ing will be used with an acquisition window of 20%
greater than the average RR interval and 20 phases will be
calculated per RR interval. The field of view will be
adapted to the individual patient to obtain optimal
images. Data will be analyzed using vendor provided soft-
ware (Argus, Siemens Medical Solutions, Erlangen, Ger-
many). Endocardial, epicardial and papillary muscle
outlines will be manually traced on end systolic and end
Blood pressure management algorithm Figure 1
Blood pressure management algorithm.
INTENSIFY 
PHARMACOLOGIC 
THERAPY OF BLOOD
PRESSURE
DECREASE “DRY”
WEIGHT
IS PATIENT AT 
TARGET WEIGHT?
DECREASE “DRY”
WEIGHT
DE-INTENSIFY 
PHARMACOLOGIC 
THERAPY OF BLOOD 
PRESSURE
IS PATIENT AT 
TARGET BLOOD 
PRESSURE?
REASSESS AT NEXT 
SCHEDULED VISIT
NO YES BP STILL HIGH
YES
NO BP 
LOWBMC Nephrology 2006, 7:2 http://www.biomedcentral.com/1471-2369/7/2
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diastolic frames. Ejection fraction, LV mass, and stroke
volume will be calculated.
Outcomes – Blood pressure
Assessment of the blood pressure outcomes will be per-
formed at baseline and month six of the study by a study
physician using a mercury sphygmomanometer following
the CHEP protocol for blood pressure measurement [23].
A five-minute rest in a quiet, comfortable room will be
used prior to measurement. Three blood pressure meas-
urements will be taken five minutes apart with the average
of the last two blood pressures used as the true blood pres-
sure.
Blood pressure control will also be evaluated by the mean
change in blood pressure parameters (systolic, diastolic,
mean arterial, and pulse pressure). The use of antihyper-
tensive medications will also be assessed at both the
entrance and exit visit and the change in the mean
number of antihypertensive medications will be com-
pared between the NHD and CvHD group.
Outcomes – Health related quality of life
Health-related quality of life questionnaires will be
administered at the time of randomization (before
patients are aware of their treatment allocation), at base-
line (i.e. month 0), and at three and six months of the
study. Consistent with published guidelines [24], HRQOL
will be assessed using a spectrum of HRQOL instruments
including a disease specific questionnaire (Kidney Disease
Quality of Life Short Form (KDQOL-SF), a generic ques-
tionnaire (Short-Form 36 (SF-36), and a preference-based
questionnaire (Euroqol (EQ-5D)) [25,26].
The EQ-5D will be used in this study as a preference-based
index measure to approximate utility scores. Questions in
the EQ-5D index focus on five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depres-
sion. The EQ-5D Index, based on health state valuations
elicited from the general public [27,28] is anchored at 0.0
(dead) and 1.0 (full health). A minimum increment of
0.03 in the EQ-5D index score can be considered clinically
important as it corresponds to the smallest coefficient for
a change from 'No problem' to 'Some problems' within a
dimension of the EQ-5D (26). Given that the EQ-5D
measures overall quality of life, the EQ-5D index score
will be the primary measure used to determine whether
NHD has an impact on HRQOL.
The KDQOL-SF includes questions targeted at particular
health-related concerns for individuals on dialysis. Scores
on each KDQOL-SF dimension range from 0 – 100, with
higher scores reflecting better HRQOL. The generic
HRQOL profile measure used in this study will be the SF-
36, which has been used in ESRD [29] and includes eight
multi-item scales describing general HRQOL issues. As
with the KDQOL-SF, scores on each dimension can range
from 0 – 100, with higher scores reflecting better HRQOL.
These measures will predominantly be measured to deter-
mine which facets of HRQOL are most impacted by NHD.
Outcomes – Anemia
Hemoglobin and hematocrit will be measured every
month throughout the study. The dose of erythropoietic
stimulating proteins and iron supplements will be
recorded for two months prior to starting the study as well
monthly for the duration of the study. The effect of the
intervention on anemia management will be primarily
assessed using the change in mean erythropoietin/hemat-
ocrit ratio. As well, since both groups may obtain similar
hemoglobin levels by the use of erythropoietin and iron,
the average doses of these medications for the two months
before study entry and the last two months of the study
will also be compared between groups.
Outcomes – Mineral metabolism
Calcium, phosphate, and albumin levels will be measured
monthly throughout the study. PTH levels will be drawn
at baseline and study exit. Information on the dose and
type of phosphate binder, and the dose, type and route of
administration for vitamin D analogs will be recorded
monthly throughout the study.
Outcomes – Costs
To enable economic evaluation of NHD, use of health
care resources and their associated costs will be collected
prospectively alongside the clinical trial. Costs to be
assessed will include the costs associated with NHD,
including the cost of training patients, the cost of neces-
sary renovations to a patient's home, the cost of the hemo-
dialysis machine, and the ongoing cost of supplies and
clinical support. The cost of providing dialysis for patients
in the conventional hemodialysis group will be assessed
as previously described [30]. In addition to collecting dial-
ysis-specific costs, we will also collect information for all
patients on associated health care costs including the cost
of hospitalization, the cost of outpatient day surgery
(including access surgery), the cost of diagnostic imaging
(including that required to maintain the patient's vascular
access), the cost of medications, and the cost of laboratory
testing [30]. Lastly, patients will complete a questionnaire
at study entry and exit to assess the non-health care related
costs associated with performing nocturnal and conven-
tional dialysis.
Statistical considerations
This will be a superiority study undertaken to test the
hypothesis that NHD leads to less LV mass progression
compared to CvHD. Based upon observational data
obtained by echocardiography (11), the baseline LV massBMC Nephrology 2006, 7:2 http://www.biomedcentral.com/1471-2369/7/2
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for both groups will be 147 +/- 8 g. To give the study the
power (1-beta = 0.95) to detect a significant (alpha = 0.05,
two-tailed test) 10 g difference in LV mass (a clinically
important and statistically detectable difference given the
use of CMR) between the 2 treatment groups, 32 patients
are needed to complete the study. Assuming 20% dropout
(due to transplantation or death over six months), 19
patients in each arm of the study will be enrolled.
All analyses will be undertaken by a data analyst blinded
to the subject treatment assignment. Summary statistics
will be used to describe the baseline characteristics of both
groups. For the primary endpoint of change in LV mass,
the intention-to-treat (ITT) approach will be used, includ-
ing all enrolled patients who have at least one cMR meas-
urement. The analysis of the primary end-point will be
based on the difference between the groups in the change
of LV mass over the study period. For patients who drop-
out of the study (death or renal transplant) before the
final cMR examination, we will assume no change in the
baseline cMR parameters for the primary ITT analyses.
This very conservative approach will likely bias the final
results towards the null hypothesis. A similar approach
will be used for the secondary endpoints (Table 2).
Exploratory secondary analyses will be performed using
an observed cases approach.
Discussion
Previous observational studies have reported regression of
LV mass with the use of NHD. Given that LV mass is a sur-
rogate measure of cardiovascular disease and is an inde-
pendent predictor of cardiac mortality [2,31], this is an
important finding which has fostered enthusiasm for
NHD as a standard offering for dialysis patients. Observa-
tional studies have also reported other clinical benefits
with NHD including improved blood pressure control
and serum phosphate. Despite these notable advantages,
NHD has not yet been compared to CvHD in a rand-
omized controlled trial. This is of paramount importance
as the effort and cost required to implement NHD as a
standard dialytic therapy may be imposing. In addition,
several interventions leading to improved health out-
comes in observational studies of dialysis patients, have
failed the "gold standard" of showing the same improve-
ments in randomized controlled trials [4,5,7].
Although this study will not be powered to detect a differ-
ence in mortality, the study design will permit conclu-
sions with respect to relevant outcomes, including LV
mass progression, control of serum phosphate and ane-
mia, and change in HRQOL. The study will also facilitate
the design of a larger randomized trial which examines
clinically relevant endpoints including mortality.
Abbreviations
CHEP – Canadian Hypertension Education Program
cMR – cardiac magnetic resonance
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EQ-5D – Euroqol 5-D
ESRD – End-stage Renal Disease
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KDQOL-SF – Kidney disease quality of life short form
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Table 2: Primary analyses for primary (LV mass) and secondary outcomes
Factor First Measure Final Measure Primary Analysis*
LV mass Baseline 6 month visit Comparison of mean change in LV 
mass for NHD vs control subjects
Blood pressure Baseline visit – average of 5 and 10 
minute readings
6 month visit – average of 5 and 10 
minute readings
Comparison of mean change in systolic 
BP for NHD vs control subjects
Quality of Life Baseline 6 month visit Difference in the 6 month and baseline 
EQ-5D index scores for NHD vs 
control group – intention to treat, last 
observation carried forward
Anemia Mean Hct and Epo administered for 
two months preceding baseline visit
Mean Hct and Epo administered for the 
final two months of the study
Mean change in hct/epo ratio for NHD 
vs control subjects
Mineral Metabolism Mean Ca*PO4 for two months 
preceding baseline visit
Mean Ca*PO4 for the final two months 
of the study
Mean change in Ca*PO4 for NHD vs 
control subjects
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RCT – randomized controlled trial
SF-36 – short form 36
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